Showing results (31-40 of 124) with videos related to
Sort By:
Pageof 13
Evolutionary Bioinformatics Online|January 30, 2016
Genome Sequence and Analysis of Peptoclostridium difficile Strain ZJCDC-S82Yun Luo, Chen Huang, Julian Ye, et al.Microbiological Research|April 29, 2025
Clca1 deficiency exacerbates colitis susceptibility via impairment of mucus barrier integrity and gut microbiota homeostasisZhi Liu, Hong Zhang, Jingjing Wang, et al.Plos One|September 29, 2021
Large-scale identification of extracellular plant miRNAs in mammals implicates their dietary intakeXi Chen, Lu Liu, Qinjie Chu, et al.JAMA Network Open|July 21, 2020
Effect of Reduced-Dose Capecitabine Plus Cetuximab as Maintenance Therapy for RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Clinical TrialLu Wang, Ying Liu, Xianli Yin, et al.British Journal of Cancer|June 30, 2018
A randomised phase II study of second-line XELIRI regimen versus irinotecan monotherapy in advanced biliary tract cancer patients progressed on gemcitabine and cisplatinYi Zheng, Xiaoxuan Tu, Peng Zhao, et al.Plos One|July 11, 2025
Biweekly CAPOX versus triweekly CAPOX in the adjuvant therapy of post-surgery CRC: A randomized controlled trialHangyu Zhang, Danyang Wang, Zhou Tong, et al.Gastroenterology Report|February 8, 2023
Oxaliplatin plus irinotecan vs irinotecan as second-line treatment in pancreatic cancer patients: a randomized-controlled open-label Phase II studyHangyu Zhang, Zhou Tong, Lulu Liu, et al.Briefings in Bioinformatics|April 9, 2020
TOD-CUP: a gene expression rank-based majority vote algorithm for tissue origin diagnosis of cancers of unknown primaryYifei Shen, Qinjie Chu, Xinxin Yin, et al.Cancer Medicine|October 19, 2021
Interleukin-33 as an early predictor of cetuximab treatment efficacy in patients with colorectal cancerXujun Zhang, Kefan Bi, Xiaoxuan Tu, et al.Cancer Science|September 17, 2021
Emerging treatment evolutions and integrated molecular characteristics of biliary tract cancersRuyi Zhang, Marco Puzzoni, Stefano Mariani, et al.Pageof 13